CollPlant Biotechnologies (CLGN) Revenue (2017 - 2026)
CollPlant Biotechnologies (CLGN) posted Revenue of $73000.0 for Q1 2026, up 21.67% on a QoQ basis from $60000.0 in Q4 2025, and down 96.45% year-over-year from $2.1 million in Q1 2025.
CollPlant Biotechnologies (CLGN) Revenue (2017 - 2026) Analysis & Trends
CollPlant Biotechnologies' Revenue history runs 10 years deep, the most recent figure standing at $73000.0 for Q1 2026.
- Quarterly Revenue fell 96.45% year-over-year to $73000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $389000.0 (down 84.26% YoY) and the FY2025 annual result came in at $2.4 million, up 360.39% from the prior year.
- Revenue was $73000.0 for Q1 2026 at CollPlant Biotechnologies, up from $60000.0 in the prior quarter.
- Across five years, Revenue topped out at $43.0 billion in Q3 2023 and bottomed at $4000.0 in Q3 2024.
- A 5-year average of $2.7 billion and a median of $136500.0 in 2022 frame the typical range for Revenue.
- Annual changes were most pronounced in 2023 — Revenue soared 39449441.28% — and 2024, when it plunged 100.0%.
- CollPlant Biotechnologies' Revenue stood at $58000.0 in 2022, then soared by 415.52% to $299000.0 in 2023, then tumbled by 45.15% to $164000.0 in 2024, then plunged by 63.41% to $60000.0 in 2025, then increased by 21.67% to $73000.0 in 2026.
- Business Quant data shows CLGN's Revenue at $73000.0 in Q1 2026, $60000.0 in Q4 2025, and $77000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,741.39 Bn | 66,741.11 Bn | - | - |
| 2 | Nanobiotix | 1,935.05 Bn | 1,934.98 Bn | - | - |
| 3 | Akari Therapeutics | 1,045.06 Bn | 1,045.06 Bn | - | - |
| 4 | BeOne Medicines | 468.98 Bn | 464.19 Bn | 1.35 Bn | 1.51 Bn |
| 5 | Vertex Pharmaceuticals | 123.24 Bn | 115.99 Bn | 2.59 Bn | 2.99 Bn |
| 6 | Regeneron Pharmaceuticals | 70.45 Bn | 61.70 Bn | 3.31 Bn | 3.61 Bn |
| 7 | Belite Bio | 63.04 Bn | 63.04 Bn | - | - |
| 8 | Argenx Se | 55.79 Bn | 50.60 Bn | 1.41 Bn | 1.56 Bn |
| 9 | Alnylam Pharmaceuticals | 37.79 Bn | 34.78 Bn | 959.66 Mn | 1.17 Bn |
| 10 | CollPlant Biotechnologies | 4.40 Mn | 4.40 Mn | -243,000.00 | 73,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 30, 2026 | 73,000.00 |
| Dec 31, 2025 | 60,000.00 |
| Sep 30, 2025 | 77,000.00 |
| Jun 30, 2025 | 179,000.00 |
| Mar 30, 2025 | 2.06 Mn |
| Dec 31, 2024 | 164,000.00 |
| Sep 30, 2024 | 4,000.00 |
| Jun 30, 2024 | 249,000.00 |
| Mar 31, 2024 | 98,000.00 |
| Dec 31, 2023 | 299,000.00 |
| Sep 30, 2023 | 43.00 Bn |
| Jun 30, 2023 | 10.18 Mn |
| Mar 31, 2023 | 433,000.00 |
| Dec 31, 2022 | 58,000.00 |
| Sep 30, 2022 | 109,000.00 |
| Jun 30, 2022 | 66,000.00 |
| Dec 31, 2021 | 310,000.00 |
| Sep 30, 2021 | 140,000.00 |
| Jun 30, 2021 | 691,000.00 |
| Mar 31, 2021 | 14.50 Mn |